Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 255A (TMEM255A), also known as FAM70A, is a predicted integral membrane protein with four transmembrane domains primarily localized to the nuclear envelope in eukaryotic cells[1][5]. The human TMEM255A gene resides on chromosome Xq24 and encodes a protein of 349 amino acids, predicted to have a molecular weight of ~38 kDa[1][5]. TMEM255A is moderately expressed in various tissues, most notably in the brain, nerve, testis, ovary, thymus, and kidney[1][4]. It may be involved in cellular processes regulated by ubiquitination and protein degradation, indicated by its predicted interaction with E3 ubiquitin ligases and other regulatory proteins[1]. Current data does not implicate TMEM255A as a receptor, transporter, enzyme, or classical therapeutic target; rather, it is a less-characterized membrane-associated protein with ongoing investigation into possible roles in cancer biology, particularly glioblastoma multiforme[1][3]. No approved drugs, validated disease biomarkers, or safety/therapeutic risk information are documented for this target at present[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 255A (TMEM255A).